Ischemia reperfusion injury, ischemic conditioning and diabetes mellitus

Journal of Molecular and Cellular Cardiology

Volumn 91, Issue , 2016, Pages 11-22

  Lejay, Anne ^a,b   Fang, Fei ^a   John, Rohan ^c   Van, Julie A D ^a   Barr, Meredith ^a   Thaveau, Fabien ^b   Chakfe, Nabil ^b   Geny, Bernard ^b   Scholey, James W ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITÉ DE STRASBOURG   (France)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; ADENOSINE TRIPHOSPHATE; ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; ADVANCED GLYCATION END PRODUCT; CALCITONIN GENE RELATED PEPTIDE; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE; COPPER ZINC SUPEROXIDE DISMUTASE; CYCLIC GMP DEPENDENT PROTEIN KINASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLYCOGEN SYNTHASE KINASE 3BETA; MANGANESE SUPEROXIDE DISMUTASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NITRIC OXIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN KINASE C; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; STAT3 PROTEIN; CALCIUM;

APOPTOSIS; CALCIUM CELL LEVEL; CALCIUM TRANSPORT; DIABETES MELLITUS; ENDOPLASMIC RETICULUM STRESS; HEART PROTECTION; HUMAN; HYPERGLYCEMIA; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; ISCHEMIC CONDITIONING; ISCHEMIC POSTCONDITIONING; ISCHEMIC PRECONDITIONING; MITOCHONDRIAL PERMEABILITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REMOTE ISCHEMIC CONDITIONING; REPERFUSION INJURY; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; CARDIAC MUSCLE; CARDIAC MUSCLE CELL; COMPLICATION; DIABETIC COMPLICATION; HEART INFARCTION PREVENTION; METABOLISM; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; PATHOLOGY;

ANIMALS; APOPTOSIS; CALCIUM; DIABETES COMPLICATIONS; DIABETES MELLITUS; ENDOPLASMIC RETICULUM STRESS; HUMANS; ISCHEMIC PRECONDITIONING, MYOCARDIAL; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; MYOCYTES, CARDIAC; OXIDATIVE STRESS; SIGNAL TRANSDUCTION;

EID: 84952941752     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2015.12.020     Document Type: Review

References (165)

1. Kalogeris T., Baines C.P., Krenz M., Korthuis R.J. Cell biology of ischemia/reperfusion injury. Int. Rev. Cell Mol. Biol. 2012, 298:229-317.
2. Kloner R.A., Schwartz Longagre L. State of the science of cardioprotection: challenges and opportunities-proceedings of the 2010 NHLBI workshop on cardioprotection. J. Cardiovasc. Pharmacol. Ther. 2011, 16:223-232.
3. Murphy E., Steenbergen C. Ion transport and energetics during cell death and protection. Physiology 2008, 23:115-123.
4. Sanada S., Komuro I., Kitakaze M. Pathophysiology of myocardial reperfusion injury: preconditioning, postconditioning, and translational aspects of protective measures. Am. J. Physiol. Heart Circ. Physiol. 2011, 301:1723-1741.
5. Walters A.M., Porter G.A., Brookes P.S. Mitochondria as a drug target in ischemic heart disease and cardiomyopathy. Circ. Res. 2012, 111:1122-1236.
6. Vinten-Johansen J., Shi W. Preconditioning and postconditioning: current knowledge, knowledge gaps, barriers to adoption, and future directions. J. Cardiovasc. Pharmacol. Ther. 2011, 16:260-266.
7. Hausenloy D.J., Yellon D.M. The therapeutic potential of ischemic conditioning: an update. Nat. Rev. Cardiol. 2011, 8:619-629.
8. Pac-Soo C.K., Mathew H., Ma D. Ischemic conditioning strategies reduce ischemia/reperfusion-induced organ injury. Br. J. Anaesth. 2015, 114:204-216.
9. Bae Y.S., Oh H., Rhee S.G., Yoo Y.D. Regulation of reactive oxygen species generation in cell signaling. Mol. Cell 2011, 32:491-509.
10. Pain T., Yang X.M., Critz S.D., Yue Y., Nakano A., Liu G.S., et al. Opening of mitochondrial KATP channels triggers the preconditioned state by generating free radicals. Circ. Res. 2000, 87:460-466.
11. Danaei G., Finukane M.M., Lu Y., Singh G.M., Cowan M.J., Cj P., et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet 2011, 378:31-40.
12. Miki T., Itoh T., Sunaga D., Miura T. Effects of diabetes on myocardial infarct size and cardioprotection by preconditioning and postconditioning. Cardiovasc. Diabetol. 2012, 11:67.
13. Whittington H.J., Babu G.G., Mocanu M.M., Yellon D.M., Hausenloy D.J. The diabetic heart: too sweet for its own good?. Cardiol. Res. Pract. 2012, 2012:845698.
14. Rolo A.P., Palmeira C.M. Diabetes and mitochondrial function: role of hyperglycemia and oxidative stress. Toxicol. Appl. Pharmacol. 2006, 212:167-178.
15. Folli F., Corradi D., Fanti P., Davalli A., Paez A., Giaccari A., et al. The role of oxidative stress in the pathogenesis of type 2 diabetes mellitus micro- and macrovascular complications: avenues for a mechanistic-based therapeutic approach. Curr. Diabetes Rev. 2011, 7:313-324.
16. Ansley D.M., Wang B. Oxidative stress and myocardial injury in the diabetic heart. J. Pathol. 2013, 229:232-241.
17. Szydlowska K., Tymianski M. Calcium, ischemia and excitoxicity. Cell Calcium 2010, 47:122-129.
18. Halestrap A.P. Calcium, mitochondria and reperfusion injury: a pore way to die. Biochem. Soc. Trans. 2006, 34:232-237.
19. Khalid M.A., Ashraf M. Direct detection of endogenous hydroxyl radical production in cultured adult cardiomyocytes during anoxia and reoxigenation. Is the hydroxyl radical really the most damaging radical species?. Circ. Res. 1993, 72:725-736.
20. 2 and generation of superoxide radical: role of cytochrome c and NADH. Free Radic. Biol. Med. 2011, 51:160-170.
21. Minamino T., Komuro I., Kitakaze M. Endoplasmic reticulum stress as a therapeutic target in cardiovascular disease. Circ. Res. 2010, 107:1071-1082.
22. Silachev D.N., Plotnikov E.Y., Pevzner I.B., Zorova L.D., Babenko V.A., Zorov S.D., et al. The mitochondrion as key regulator of ischaemic tolerance injury. Heart Lung Circ. 2014, 23:897-904.
23. Hausenloy D.J., Yellon D.M. The mitochondrial permeability transition pore: its fundamental role in mediating cell death during ischemia and reperfusion. J. Mol. Cell. Cardiol. 2003, 35:339-341.
24. Murphy E., Steenbergen C. What makes the mitochondria a killer? Can we condition them to be less destructive?. Biochim. Biophys. Acta 1813, 2011:1302-1308.
25. Bernardi P., Di Lisa F. The mitochondrial permeability transition pore: molecular nature and role as a target in cardioprotection. J. Mol. Cell. Cardiol. 2015, 78:100-106.
26. Sloan R.C., Moukdar F., Frasier C.R., Patel H.D., Bostian P.A., Lust R.M., et al. Mitochondrial permeability transition in the diabetic heart: contributions of thiol redox state and mitochondrial calcium to augmented reperfusion injury. J. Mol. Cell. Cardiol. 2012, 52:1009-1018.
27. Morciano G., Giorgi C., Bonora M., Punzetti S., Pavasini R., Wieckowski M.R., et al. Molecular identity of the mitochondrial permeability transition pore and its role in ischemia-reperfusion injury. J. Mol. Cell. Cardiol. 2015, 78:142-153.
28. Di Paola M., Lorusso M. Interaction of free fatty acids with the mitochondria: coupling, uncoupling and permeability transition. Biochim. Biophys. Acta 1757, 2006:1330-1337.
29. Morgan M.J., Kim Y.S., Liu Z.G. TNFα and reactive oxygen species in necrotic cell death. Cell Res. 2008, 18:343-349.
30. Kvietys P.R., Granger D.N. Role of reactive oxygen and nitrogen species in the vascular responses to inflammation. Free Radic. Biol. Med. 2012, 52:556-592.
31. Heusch G. Molecular basis of cardioprotection. Signal transduction in ischemic pre-, post, and remote conditioning. Circ. Res. 2015, 116:674-699.
32. Murry C.E., Jennings R.B., Reimer K.A. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 1986, 74:1124-1136.
33. Hausenloy D.J., Yellon D.M. The second window of preconditioning (SWOP). Where are we now?. Cardiovasc. Drugs Ther. 2010, 24:235-254.
34. Zhao Z.Q., Corvera J.S., Halkos M.E., Kerendi F., Wang N.P., Guyton R.A., et al. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. Am. J. Physiol. Heart Circ. Physiol. 2003, 285:579-588.
35. Ovize M., Baxter G.F., Di Lisa F., Ferdinandy P., Garcia-Dorado D., Hausenloy D.J., et al. Postconditioning and protection from reperfusion injury: where do we stand?. Cardiovasc. Res. 2010, 87:406-423.
36. Ovize M., Thibault H., Przyklenk K. Myocardial conditioning: opportunities for clinical translation. Circ. Res. 2013, 113:439-450.
37. Schultz R., Kelm M., Heusch G. Nitric oxide in myocardial ischemia/reperfusion injury. Cardiovasc. Res. 2004, 61:402-413.
38. Ohta A., Stkovsky M. Role of G-protein-coupled adenosine receptors in dowregulation of inflammation and protection from tissue damage. Nature 2001, 414:916-920.
39. Merighi S., Borea P.A., Gessi S. Adenosine receptors and diabetes: focus on the A2b adenosine receptor subtype. Pharmacol. Res. 2015, 99:229-236.
40. Hausenloy D.J., Tsang A., Yellon D.M. The reperfusion injury salvage kinase pathway: a common target for both ischemic preconditioning and postconditioning. Trends Cardiovasc. Med. 2005, 15:69-75.
41. Kin H., Zatta A.J., Lofye M.T., Amerson B.S., Halkos M.E., Kerendi F., et al. Post-conditioning reduces infarct size via adenosine receptor activation by endogenous adenosine. Cardiovasc. Res. 2005, 67:124-133.
42. Lecour S. Activation of the protective Survivor Activating Factor Enhancement (SAFE) pathway against reperfusion injury: does it go beyond the RISK pathway?. J. Mol. Cell. Cardiol. 2009, 47:32-40.
43. Tan B., He S.Y., Deng H.W., Li Y.J. Role of calcitonin gene-related peptide in nitric oxide-mediated myocardial delayed preconditioning induced by head stress. Acta Pharmacol. Sin. 2001, 22:851-856.
44. Xuan Y.T., Guo Y., Zhu Y., et al. Role of the protein kinase C-epsilon-Raf1-MEK-1/2-p44/42 MAPK signaling cascade in the activation of signal transducers and activators of transcription 1 and 3 and induction of cyclooxygenase-2 after ischemic preconditioning. Circulation 2005, 112:1971-1978.
45. Costa A.D., Garlid K.D. Intramitochondrial signaling: interactions among mitoKATP, PKCepsilon, ROS, and MPT. Am. J. Physiol. Heart Circ. Physiol. 2008, 295:874-882.
46. Kuno A., Critz S.D., Cui L., Solodushko V., Yang X.M., Krahn T., et al. Protein kinase C protects preconditioned rabbit hearts by increasing sensitivity of adenosine A2b-dependent signaling during early reperfusion. J. Mol. Cell. Cardiol. 2007, 43:262-271.
47. Oldenburg O., Qin Q., Krieg T., Yang X.M., Philipp S., Critz S.D., et al. Bradykinin induces mitochondrial ROS generation via NO, cGMP, PKG, and mitoKATP channel opening and leads to cardioprotection. Am. J. Physiol. Heart Circ. Physiol. 2004, 286:468-476.
48. Inserte J., Barba I., Ponselas-Nozal M., Hernando V., Aguilo L., Ruiz-Meana M., et al. cGMP/PKG pathway mediates myocardial postconditioning protection in rat hearts by delaying normalization of intracellular acidosis during reperfusion. J. Mol. Cell. Cardiol. 2011, 50:903-909.
49. Hausenloy D.J., Yellon D.M. Reperfusion injury salvage kinase signaling: taking a RISK for cardioprotection. Heart Fail. Rev. 2007, 79:217-234.
50. Bell R.M., Yellon D.M. Conditioning the whole heart - not just the cardiomyocyte. J. Mol. Cell. Cardiol. 2012, 53:24-32.
51. Davidson S.M., Hausenloy D., Duchen M.R., Yellon D.M. Signaling via the reperfusion injury signaling kinase (RISK) pathway links closure of the mitochondrial permeability transition pore to cardioprotection. Int. J. Biochem. Cell Biol. 2006, 38:414-419.
52. Heusch G., Boengler K., Schultz R. Inhibition of mitochondrial permeability transition pore opening: the holy grail of cardioprotection. Basic Res. Cardiol. 2010, 105:151-154.
53. Nishihara M., Miura T., Miki T., Tanno M., Yano T., Naitoh K., et al. Modulation of the mitochondrial permeability transition pore complex in GSK-3beta-mediated myocardial protection. J. Mol. Cell. Cardiol. 2007, 43:564-570.
54. Ong S.B., Hall A.R., Dongworth R.K., Kalkhoran S., Pyakurel A., Scorrano L., et al. Akt protects the heart against ischemia-reperfusion injury by modulating mitochondrial morphology. Thromb. Haemost. 2015, 113:513-521.
55. Boengler K., Hilfiker-Kleiner D., Heusch G., Schulz R. Inhibition of permeability transition pore opening by mitochondrial STAT3 and its role in myocardial ischemia/reperfusion. Basic Res. Cardiol. 2010, 105:771-785.
56. Ardehali H., O'Rourke B. Mitochondrial K(ATP) channels in cell survival and death. J. Mol. Cell. Cardiol. 2005, 39:7-16.
57. Wegrzyn J., Potla R., Chwae Y.J., Sepuri N.B., Zhang Q., Koeck T., et al. Function of mitochondria STAT3 in cellular respiration. Science 2009, 323:793-797.
58. Ruiz-Meana M., Fernandez-Sanz C., Garcia-Dorado D. The SR-mitochondria interaction: a new player in cardiac pathophysiology. Cardiovasc. Res. 2010, 88:30-39.
59. Abdallah Y., Kasseckert S.A., Iraqi W., Said M., Shahzad T., Erdogan A., et al. Interplay between Ca2+ cycling and mitochondrial permeability transition pores promotes reperfusion-induced injury of cardiac myocytes. J. Cell. Mol. Med. 2011, 15:2478-2485.
60. Nakamura Y., Miura T., Nakano A., Ichikawa Y., Yano T., Kobayashi H., et al. Role of microtubules in ischemic preconditioning against myocardial infarction. Cardiovasc. Res. 2004, 64:465-473.
61. Halliwell B. Free radicals, antioxidants, and human disease: curiosity, cause, or consequence?. Lancet 1994, 344:721-724.
62. Baynes J.W., Thrope S.R. Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes 1999, 48:1-9.
63. Del Valle H.F., Lascano E.C., Negroni J.A. Ischemic preconditioning protection against stunning in conscious diabetic sheep: role of glucose, insulin, sarcolemmal and mitochondrial KATP channels. Cardiovasc. Res. 2002, 55:642-659.
64. Wei W., Liu Q., Tan Y., Liu L., Li X., Cai L. Oxidative stress, diabetes, and diabetic complications. Hemoglobin 2009, 33:370-377.
65. Giacco F., Brownlee M. Oxidative stress and diabetic complications. Circ. Res. 2010, 107:1058-1070.
66. Itoh T., Kouzu H., Miki T., Tanno M., Kuna A., Sato T., et al. Cytoprotective regulation of the mitochondrial permeability transition pore is impaired in type 2 diabetic Goto-Kakizaki rat hearts. J. Mol. Cell. Cardiol. 2012, 53:870-879.
67. Guzik T.J., Mussa S., Gastaldi D., Sadowski J., Ratnatunga C., Pillai R., et al. Mechanisms of increased vascular superoxide production in human diabetes mellitus: role of NADPH oxidase and endothelial nitric oxide synthase. Circulation 2002, 105:1656-1662.
68. Matsushima S., Kinugawa S., Yokota T., Inoue N., Ohta Y., Hamaguchi S., et al. Increased myocardial NADPH oxidase-derived superoxide causes the exacerbation of postinfarct heart failure in type 2 diabetes. Am. J. Physiol. Heart Circ. Physiol. 2009, 297:400-416.
69. Ramakrishna V., Jaikhani R. Oxidative stress in non-insulin-dependent diabetes mellitus patients. Acta Diabetol. 2008, 45:41-46.
70. Takayanagi R., Inoguchi T., Ohnala K. Clinical and experimental evidence for oxidative stress as an exacerbating factor of diabetes mellitus. J. Clin. Biochem. Nutr. 2011, 48:72-77.
71. + exchanger protects diabetic and non-diabetic hearts from ischemic injury: insight into altered susceptibility of diabetic hearts to ischemic injury. J. Mol. Cell. Cardiol. 1999, 31:785-795.
72. Nishikawa T., Edelstein D., Du X.L., Yamagishi S., Matsumura T., Kaneda Y., et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000, 404:787-790.
73. Nishikawa T., Edelstein D., Brownlee M. The missing link: a single unifying mechanism for diabetic complications. Kidney Int. 2000, 77:26-30.
74. Echtay K.S., Roussel D., St-Pierre J., Jakabsons M.B., Cadenas S., Stuart J.A., et al. Superoxide activates mitochondrial uncoupling proteins. Nature 2002, 415:96-99.
75. Piconi L., Quagliaro L., Assaloni R., Da Ros R., Maier A., Zuodar G., et al. Constant and intermittent high glucose enhances endothelial cell apoptosis through mitochondrial superoxide overproduction. Diabetes Metab. Res. Rev. 2006, 22:198-203.
76. Monnier L., Mas E., Ginet C., Michel F., Villon L., Cristol J.P., et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 2006, 295:1681-1687.
77. Lewis P., Stefanovic N., Pete J., Calkin A.C., Giunti S., Thallas-Bonke V., et al. Lack of the antioxidant enzyme glutathione peroxidase 1 accelerates atherosclerosis in diabetic apolipoprotein E deficient mice. Circulation 2007, 115:2178-2187.
78. Wenthlot I.M., Kulik W., Michels F., Hoekstra J.B., De Vries J.H. Glucose fluctuations and activation of oxidative stress in patients with type 1 diabetes. Diabetologia 2008, 51:183-190.
79. Horvath E.M., Benko R., Kiss L., Muranyi M., Pek T., Fekete K., et al. Rapid "glycaemic swings" induce introsative stress, activate poly(ADP-ribose) polymerase and impair endothelial function in a rat model of diabetes mellitus. Diabetologia 2009, 52:952-961.
80. Anderson E.J., Kypson A.P., Rodriguez E., Anderson C.A., Lehr E.J., Neufer P.D. Substrate-specific derangements in mitochondrial metabolism and redox balance in the atrium of the type 2 diabetic human heart. J. Am. Coll. Cardiol. 2009, 54:1891-1898.
81. Bugger H., Abel E.D. Mitochondria in the diabetic heart. Cardiovasc. Res. 2010, 88:229-240.
82. Raedschelders K., Ansley D.M., Chen D.D.Y. The cellular and molecular origin of reactive oxygen species generation during myocardial ischemia and reperfusion. Pharmacol. Ther. 2012, 133:230-255.
83. Miki T., Yuda S., Kouzu H., Miura T. Diabetic cardiomyopathy: pathophysiology and clinical features. Heart Fail. Rev. 2013, 18:149-166.
84. Chen J., Zhang Z., Cai L. Diabetic cardiomyopathy and its prevention by nrf2: current status. Diabetes Metab. J. 2014, 38:337-345.
85. Lenaz G., Bovina C., D'Aurelio M., Fato R., Formiggini G., Genova M.L., et al. Role of mitochondria in oxidative stress and aging. Ann. N. Y. Acad. Sci. 2002, 959:199-213.
86. Sack M.N. Type 2 diabetes, mitochondrial biology and the heart. J. Mol. Cell. Cardiol. 2009, 46:842-849.
87. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001, 414:813-820.
88. Du X.L., Edelstein D., Dimmeler S., Ju Q., Sui C., Brownlee M., et al. Hyperglycemia inhibits endothelial nitric oxide synthase activity by posttranslational modification at the Akt site. J. Clin. Invest. 2001, 108:1341-1348.
89. Banke N.H., Lewandowski E.D. Impaired cytosolic NADH shuttling and elevated UCP3 contribute to inefficient citric acid cycle flux support in postischemic cardiac work in diabetic hearts. J. Mol. Cell. Cardiol. 2015, 79:13-20.
90. Dikalov S. Cross talk between mitochondria and NADPH oxidases. Free Radic. Biol. Med. 2011, 51:1289-1301.
91. Sumimoto H. Structure, regulation and evolution of Nox-family NADPH oxidases that produce reactive oxygen species. FEBS J. 2008, 275:3249-3277.
92. Picchi A., Gao X., Belmadani S., Potter B.J., Focardi M., Chilian W.M., et al. Tumor necrosis factor-alpha induces endothelial dysfunction in the prediabetic metabolic syndrome. Circ. Res. 2006, 99:69-77.
93. Okazaki T., Otani H., Shimazu T., Yoshioka K., Fujita M., Iwasaka T. Ascorbic acid and N-acetyl cysteine prevent uncoupling of nitric oxide synthase and increase tolerance to ischemia/reperfusion injury in diabetic rat heart. Free Radic. Res. 2011, 45:1173-1183.
94. Sheikh-Ali M., Chehade J.M., Mooradian A.D. The antioxidant paradox in diabetes mellitus. Am. J. Ther. 2011, 18:266-278.
95. Ilkun O., Boudina S. Cardiac dysfunction and oxidative stress in the metabolic syndrome: an update on antioxidant therapies. Curr. Pharm. Des. 2013, 19:4806-4817.
96. Cosentino F., Hishikawa K., Katusic Z.S., Luscher T.F. High glucose increases nitric oxide synthase expression and superoxide anion generation in human aortic endothelial cells. Circulation 1997, 96:25-28.
97. Srinivasan S., Hatley M.E., Bolick D.T., Palmer L.A., Edelstein D., Brownlee M., et al. Hyperglycaemia-induced superoxide production decreases eNOS expression via AP-1 activation in aortic endothelial cells. Diabetologia 2004, 47:1727-1734.
98. Song F., Jia W., Yao Y., Hu Y., Lei L., Lin J., et al. Oxidative stress, antioxidant status and DNA damage in patients with impaired glucose regulation and newly diagnosed type 2 diabetes. Clin. Sci. 2007, 112:599-606.
99. Song P., Wu Y., Xu J., Xie Z., Dong Y., Zhang M., et al. Reactive nitrogen species induced by hyperglycemia suppresses Akt signaling and triggers apoptosis by upregulating phosphatase PTEN (phosphatase and tensin homologue deleted on chromosome 10) in a LKB1-dependent manner. Circulation 2007, 116:1585-1595.
100. Baraka-Vidot J., Guerin-Duborg A., Dubois F., Payet B., Bourdon E., Rondeau P. New insights into deleterious impacts of in vivo glycation on albumin antioxidant activities. Biochim. Biophys. Acta 1830, 2013:3532-3541.
101. Saisho Y. Glycemic variability and oxidative stress: a link between diabetes and cardiovascular disease?. Int. J. Mil. Sci. 2014, 15:18381-18406.
102. Ceriello A., Morocutti A., Mercuri F., Quagliaro L., Moro M., Damante G., et al. Defective intracellular antioxidant enzyme production in type 1 diabetic patients with nephropathy. Diabetes 2000, 49:2170-2177.
103. Michiels C., Raes M., Toussaint O., Remacle J. Importance of Se-gluthatione peroxidase, catalase and Cu/sn-SOD for cell survival against oxidative stress. Free Radic. Biol. Med. 1994, 17:235-248.
104. Ferdinandy P., Hausenloy D.J., Heusch G., Baxter G.F., Schulz R. Interaction of risk factors, comorbidities, and comedications with ischemia/reperfusion injury and cardioprotection by preconditioning, postconditioning, and remote conditioning. Pharmacol. Rev. 2014, 66:1142-1174.
105. Wider J., Przyklenk K. Ischemic conditioning: the challenge of protecting the diabetic heart. Cardiovasc. Diagn. Ther. 2014, 4:383-396.
106. Rana A., Goyal N., Ahlawat A., Jamwal S., Reddy B.V., Sharma S. Mechanisms involved in attenuated cardio-protective role of ischemic preconditioning in metabolic disorders. Perfusion 2015, 30:94-105.
107. Przyklenk K. Reduction of myocardial infarct size with ischemic conditioning: physiologic and technical considerations. Anesth. Analg. 2013, 117:891-901.
108. Kristiansen S.B., Lofgren B., Stottrup N.B., Lhatir D., Nielsen-Kudsk J.E., Nielsen T.T., et al. Ischaemic preconditioning does not protect the heart in obese and lean animal models of type 2 diabetes. Diabetologia 2004, 47:1716-1721.
109. Katakam P.V., Jordan J.E., Snipes J.A., Tulbert C.D., Miller A.W., Busija D.W. Myocardial preconditioning against ischemia-reperfusion injury is abolished in Zucker obese rats with insulin resistance. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2007, 292:920-926.
110. Zhu S.G., Xi L., Kukreja R.C. Type 2 diabetic obese db/db mice are refractory to myocardial ischaemic postconditioning in vivo: potential role for Hsp20, F1-ATPase delta and Echs 1. J. Cell. Mol. Med. 2012, 16:950-958.
111. Whittington H.J., Harding I., Stephenson C.I., Bell R., Hausenloy D.J., Mocanu M.M., et al. Cardioprotection in the aging, diabetic heart: the loss of protective Akt signaling. Cardiovasc. Res. 2013, 99:694-704.
112. Kersten J.R., Toller W.G., Gross E.R., Pagel P.S., Waritier D.C. Diabetes abolishes ischemic preconditioning: role of glucose, insulin, and osmolality. Am. J. Physiol. Heart Circ. Physiol. 2000, 278:1218-1224.
113. Nieszner E., Posa I., Kocsis E., Pogatsa G., Preda I., Koltai M.Z. Influence of diabetic state and that of different sulfonylureas on the size of myocardial infarction with and without ischemic preconditioning in rabbits. Exp. Clin. Endocrinol. Diabetes 2002, 110:212-218.
114. Ferdinandy P., Schultz R., Baxter G.F. Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning. Pharmacol. Rev. 2007, 59:418-458.
115. Yadav H.N., Singh M., Sharma P.L. Modulation of the cardioprotective effect of ischemic preconditioning in hyperlipidaemic rat heart. Eur. J. Pharmacol. 2010, 643:78-83.
116. Yadav H.N., Singh M., Sharma P.L. Involvement of GSK-3β in attenuation of the cardioprotective effect of ischemic preconditioning in diabetic rat heart. Mol. Cell. Biochem. 2010, 343:75-81.
117. Ji L., Zhang X., Liu W., Huang Q., Fu F., Ma H., et al. AMPK-regulated and Akt-dependent enhancement of glucose uptake is essential in ischemic preconditioning-alleviated reperfusion injury. PLoS ONE 2013, 8:69910.
118. Przyklenk K., Maynard M., Greiner D.L., Whittaker P. Cardioprotection with postconditioning: loss of efficacy in murine models of type-2 and type-1 diabetes. Antioxid. Redox Signal. 2011, 14:781-790.
119. Przyklenk K. Efficacy of cardioprotective conditioning strategies in aging and diabetic cohorts: the comorbidity conundrum. Drugs Aging 2011, 28:331-343.
120. Bouhidel O., Pons S., Souktani R., Zini R., Berdeaux A., Ghaleh B. Myocardial ischemic postconditioning against ischemia-reperfusion is impaired in ob/ob mice. Am. J. Physiol. Heart Circ. Physiol. 2008, 295:1580-1586.
121. Wagner C., Kloeting I., Strasser R.H., Weinbrenner C. Cardioprotection by postconditioning is lost in WOKW rats with metabolic syndrome: role of glycogen synthase kinase 3 beta. J. Cardiovasc. Pharmacol. 2008, 52:430-437.
122. Zhu X.H., Yuan H.J., Wu Y.N., Kang Y., Jiao J.J., Gao W.Z., et al. Non-invasive limb ischemic pre-conditioning reduces oxidative stress and attenuates myocardium ischemia-reperfusion injury in diabetic rats. Free Radic. Res. 2011, 45:201-210.
123. Badalzadeh R., Mohammadi M., Najafi M., Ahmadiasl N., Farajnia S., Ebrahimi H. The additive effects of ischemic postconditioning and cyclosporine-A on nitric oxide activity and functions of diabetic myocardium injured by ischemia/reperfusion. J. Cardiovasc. Pharmacol. Ther. 2012, 17:181-189.
124. Oosterlinck W., Dresselaers T., Geldhof V. Diabetes mellitus and the metabolic syndrome do not abolish, but might reduce, the cardioprotective effect of ischemic postconditioning. J. Thorac. Cardiovasc. Surg. 2013, 145:1595-1602.
125. Najafi M., Farajnia S., Mohammadi M., Badalzadzh R., Ahmadi Asl N., Baradaran B., et al. Inhibition of mitochondrial permeability transition pore restores the cardioprotection by postconditioning in diabetic hearts. J. Diabetes Metab. Disord. 2014, 13:106.
126. Eckle T., Krahn T., Grenz A. Cardioprotection by ecto-5'-nucleotidase (CD73) and A2B adenosine receptors. Circulation 2007, 115:1581-1590.
127. Podgorska M., Kocbuch K., Grden M., Szutowicz A., Pawelczyk T. Reduced ability to release adenosine by diabetic rat cardiac fibroblasts due to altered expression of nucleoside transporters. J. Physiol. 2006, 576:179-189.
128. Guzman-Flores J.M., Cortes-Espinosa N., Cortes-Garcia J., Vargas-Morales J.M., Catano-Canizalez Y.G., Rodriguez-Rivera J.G., et al. Expression of CD73 and A2A receptors in cells from subjects with obesity and type 2 diabetes mellitus. Immunobiol 2015, 220:976-984.
129. Song P., Wu Y., Xu J., Xie Z., Dong Y., Zhang M., et al. Reactive nitrogen species induced by hyperglycemia suppresses Akt signaling and triggers apoptosis by upregulating phosphatase PTEN (phosphatase angiotensin homologue deleted on chromosome 10) in an LKB1-dependent manner. Circulation 2007, 116:1585-1595.
130. Mocanu N.M., Yellon D.M. PTEN, the Achilles' heel of myocardial ischaemia/reperfusion injury?. Br. J. Pharmacol. 2007, 150:833-838.
131. Wang B., Raedschelders K., Shravah J., Hui Y., Safaei H.G., Chen D.D., et al. Differences in myocardial PTEN expression and Akt signaling in type 2 diabetic and nondiabetic patients undergoing coronary bypass surgery. Clin. Endocrinol. 2011, 74:705-713.
132. Fullmer T.M., Pei S., Zhu Y., Sloan C., Manzanares R., Henrie B., et al. Insulin suppresses ischemic preconditioning-mediated cardioprotection through Akt-dependent mechanisms. J. Mol. Cell. Cardiol. 2013, 64:20-29.
133. Tsang A., Hausenloy D.J., Mocanu M.M., Carr R.D., Yellon D.M. Preconditioning the diabetic heart: the importance of Akt phosphorylation. Diabetes 2005, 54:2360-2364.
134. Gross E.R., Hsu A.K., Gross G.J. Diabetes abolishes morphine-induced cardioprotection via multiple pathways upstream of glycogen synthase kinase-3 beta. Diabetes 2007, 56:787-795.
135. Xia R., Zhao B., Wu Y., Hou J.B., Zhang L., Xu J.J., et al. Ginsenoside Rb1 conditioning enhances eNOS expression and attenuates myocardial ischemia/reperfusion injury in diabetic rats. J. Biomed. Biotechnol. 2011, 2011:667930.
136. Kim H.S., Cho J.E., Hwang K.C., Shim Y.H., Lee J.H., Kwak Y.L. Diabetes mellitus mitigates cardioprotective effects of remifentanil preconditioning in ischemia-reperfused rat hearts in association with antiapoptotic pathways of survival. Eur. J. Pharmacol. 2010, 628:132-139.
137. Miki T., Miura T., Hotta H., Tanno M., Yano T., Sato T., et al. Endoplasmic reticulum stress in diabetic hearts abolishes erythropoietin-induced myocardial protection by impairment of phospho-glycogen synthase kinase-3beta-mediated suppression of mitochondrial permeability transition. Diabetes 2009, 58:2863-2872.
138. Drenger B., Ostrovsky I.A., Barak M., Nechemia-Arbely Y., Ziv E., Axelrid J.H. Diabetes blockade of sevoflurane postconditioning is not restored by insulin in the rat heart: phosphorylated signal transducer and activator of transcription 3- and phosphatidylinositol 3-kinase-mediated inhibition. Anesthesiology 2011, 114:1364-1372.
139. Hotta H., Miura T., Miki T., Togashi N., Maeda T., Kim S.J., et al. Angiotensin II type I receptor-mediated upregulation of calcineurin activity underlies impairment of cardioprotective signaling in diabetic hearts. Circ. Res. 2010, 106:129-132.
140. Ajmani P., Yadav H.N., Singh M., Sharma P.L. Possible involvement of caveolin in attenuation of cardioprotective effect of ischemic preconditioning in diabetic rat heart. BMC Cardiovasc. Disord. 2011, 11:43.
141. Zheng L.R., Han J., Yao L., Sun Y.L., Jiang D.M., Hu S.J., et al. Up-regulation of calcitonin gene-related peptide protects streptozotocin-induced diabetic hearts from ischemia/reperfusion injury. Int. J. Cardiol. 2012, 156:192-198.
142. Hassouna A., Loubani M., Matata B.M., Fowler A., Standen N.B., Galinanes M. Mitochondrial dysfunction as the cause of the failure to precondition the diabetic human myocardium. Cardiovasc. Res. 2006, 69:450-458.
143. Sharma A.K., Hkanna D. Diabetes mellitus associated cardiovascular signaling alteration: a need for the revisit. Cell. Signal. 2013, 25:1149-1155.
144. Go A.S., Mozaffarian D., Roger V.L., Benjamin E.J., Berry J.D., Blaha M.J., et al. Heart disease and stroke statistics - 2014 update: a report from the American Heart Association. Circulation 2014, 129:28-292.
145. Sarwar N., Gao P. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010, 375:2215-2222.
146. Krempf M., Parhofer K.G., Steg P.G., Bhatt D.L., Ohman E.M., Röther J., et al. Cardiovascular event rates in diabetic and nondiabetic individuals with and without established atherothombosis. Am. J. Cardiol. 2010, 105:667-671.
147. Alegria J.R., Miller T.D., Gibbons R.J., Yi Q.L., Yusuf S. Infarct size, ejection fraction, and mortality in diabetic patients with acute myocardial infarction treated with thrombolytic therapy. Am. Heart J. 2007, 154:743-750.
148. Murcia A.M., Hennekens C.H., Lamas G.A., Jimenez-Navarro M., Rouleau J.L., Flaker G.C., et al. Impact of diabetes on mortality in patients with myocardial infarction and left ventricular dysfunction. Arch. Intern. Med. 2004, 164:2273-2279.
149. Heusch G. Cardioprotection: chances and challenges of its translation to the clinic. Lancet 2013, 381:166-175.
150. Schevchuck A., Laskey W.K. Ischemic conditioning as an adjunct to percutaneous coronary intervention. Circ. Cardiovasc. Interv. 2013, 6:484-492.
151. Healy D.A., Khan W.A., Wong C.S., Moloney M.C., Grace P.A., Coffey J.C., et al. Remote preconditioning and major clinical complications following adult cardiovascular surgery: systematic review and meta-analysis. Int. J. Cardiol. 2014, 176:20-31.
152. Kupai K., Csonka C., Fekete V., Odendaai L., van Rooyen J., Marais de W., et al. Cholesterol diet-induced hyperlipidemia impairs the cardioprotective effect of postconditioning: role of peroxynitrite. Am. J. Phys. 2009, 297:1729-1735.
153. Raphael J., Gozal Y., Navot N., Zuo Z. Hyperglycemia inhibits anesthetic-induced postconditioning in the rabbit heart via modulation of phosphatidylinositol-3-kinase/Akt and endothelial nitric oxide synthase signaling. J. Cardiovasc. Pharmacol. 2010, 55:348-357.
154. Ghaboura N., Tamareille S., Ducluzeau P., Grimaud L., Loufrani L., Croué A., et al. Diabetes mellitus abrogates erythropoietin-induced cardioprotection against ischemic-reperfusion injury by alteration of the RISK/GSK-3β signaling. Basic Res. Cardiol. 2011, 106:147-162.
155. Yetgin T., Magro M., Manintveld O.C., Nauta S.T., Cheng J.M., den Uil C.A., et al. Impact of multiple balloon inflations during primary percutaneous coronary intervention on infarct size and long-term clinical outcomes in ST-segment elevation myocardial infarction: real-world postconditioning. Basic Res. Cardiol. 2014, 109:403.
156. Xu X., Zhou Y., Luo S., Zhang W., Yu M., Ma Q., et al. Effect of remote ischemic preconditioning in the elderly patients with coronary artery disease with diabetes mellitus undergoing elective drug-eluting stent implantation. Angiology 2014, 65:660-666.
157. Jensen R.V., Stottrup N.B., Kristiansen S.B., Botker H.E. Release of a humoral circulating cardioprotective factor by remote ischemic preconditioning is dependent on preserved neural pathways in diabetic patients. Basic Res. Cardiol. 2012, 107:285.
158. Saxena P., Newman M.A., Shehatha J.S., Redington A.N., Kostantinov I.E. Remote ischemic conditioning: evolution of the concept, mechanisms, and clinical application. J. Card. Surg. 2010, 25:127-134.
159. Jensen R.V., Zachara N.E., Nielsen P.H., Kimose H.H., Kristiansen S.B., Botker H.E. Impact of O-GlcNAc on cardioprotection by remote ischaemic preconditioning in non-diabetic and diabetic patients. Cardiovasc. Res. 2013, 97:369-378.
160. Jamwal S., Kumar K., Reddy B.V. Beneficial effect of zinc chloride and zinc ionophore pyrithione on attenuated cardioprotective potential of preconditioning phenomenon in STZ-induced diabetic rat heart. Perfusion 2015, (in press).
161. Badalzadeh R., Mohammadi M., Najafi M., Ahmadiasl N., Farajnia S., Ebrahimi H. The additive effects of ischemic postconditioning and cyclosporine-A on nitric oxide activity and functions of diabetic myocardium injured by ischemia/reperfusion. J Cardiovasc. Pharmacol. Ther. 2012, 17:181-189.
162. Najafi M., Farajnia S., Mohammadi M., Badalsadeh R., Ahmadi Asl N., Baradaran B., et al. Inhibition of mitochondrial permeability transition pore restores the cardioprotection by postconditioning in diabetic hearts. J. Diabetes Metab. Disord. 2014, 13:106.
163. Gu W., Kehl F., Krolikowski J.G., Pagel P.S., Warltier D.C., Kersten J.R. Simvastatin restores ischemic preconditioning in the presence of hyperglycemia through a nitric oxide-mediated mechanism. Anesthesiology 2008, 108:634-642.
164. Hausenloy D.J., Wynne A.M., Mocanu M.M., Yellon D.M. Glimepiride treatment facilitates ischemic preconditioning in the diabetic heart. J. Cardiovasc. Pharmacol. Ther. 2013, 18:263-269.
165. Hausenloy D.J., Whittington H.J., Wynne A.M., Begum S.S., Theodorou L., Riksen N., et al. Dipeptidyl peptidase-4 inhibitors and GLP-1 reduce myocardial infarct size in a glucose-dependent manner. Cardiovasc. Diabetol. 2013, 12:154.